Dasatinib

LY2835219 is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively.

InformationADH-503 ADH-503 ((Z)-Leukadherin-1 choline) is an orally active and allosteric agonist of CD11b. ADH-503 leads to the repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid

InformationADH-503 ADH-503 ((Z)-Leukadherin-1 choline) is an orally active and allosteric agonist of CD11b. ADH-503 leads to the repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid

InformationADH-503 ADH-503 ((Z)-Leukadherin-1 choline) is an orally active and allosteric agonist of CD11b. ADH-503 leads to the repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid

InformationADH-503 ADH-503 ((Z)-Leukadherin-1 choline) is an orally active and allosteric agonist of CD11b. ADH-503 leads to the repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid

InformationADH-503 ADH-503 ((Z)-Leukadherin-1 choline) is an orally active and allosteric agonist of CD11b. ADH-503 leads to the repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid

InformationADH-503 ADH-503 ((Z)-Leukadherin-1 choline) is an orally active and allosteric agonist of CD11b. ADH-503 leads to the repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid

b-Cembrenediol is an inhibitor of tumor promotion. Novel c-Met inhibitors which are used in anticancer treatments.

b-Cembrenediol is an inhibitor of tumor promotion. Novel c-Met inhibitors which are used in anticancer treatments.

b-Cembrenediol is an inhibitor of tumor promotion. Novel c-Met inhibitors which are used in anticancer treatments.

Selective inhibitor of IDH1 R132H and R132C mutants in vitro (IC₅₀s = 0.07 and 0.

Selective inhibitor of IDH1 R132H and R132C mutants in vitro (IC₅₀s = 0.07 and 0.